Cargando…

Pin1–FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?

Detalles Bibliográficos
Autor principal:	de Keizer, Peter LJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094623/ https://www.ncbi.nlm.nih.gov/pubmed/30190884 http://dx.doi.org/10.2217/mmt-2016-0010

Ejemplares similares

Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling
por: Kruiswijk, F, et al.
Publicado: (2016)

Investigation of FOXM1 as a Potential New Target for Melanoma
por: Miyashita, Azusa, et al.
Publicado: (2015)

FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients
por: Klinhom-on, Nathakan, et al.
Publicado: (2021)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics
por: Yu, Ji Hoon, et al.
Publicado: (2020)

FoxM1 Is a General Target for Proteasome Inhibitors
por: Bhat, Uppoor G., et al.
Publicado: (2009)

The oncogenic transcription factor FOXM1 and anticancer therapy
por: Gartel, Andrei L.
Publicado: (2012)

MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
por: Branigan, Timothy B., et al.
Publicado: (2021)

Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors
por: Gartel, Andrei L.
Publicado: (2014)

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma
por: Colón-Bolea, Paula, et al.
Publicado: (2021)

Nucleophosmin Interacts with PIN2/TERF1-interacting Telomerase Inhibitor 1 (PinX1) and Attenuates the PinX1 Inhibition on Telomerase Activity
por: Cheung, Derek Hang-Cheong, et al.
Publicado: (2017)

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
por: Maekawa, Akira, et al.
Publicado: (2016)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
por: Sundaramurthi, Husvinee, et al.
Publicado: (2022)

FOXM1: A potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma
por: Xiao, Zhaohua, et al.
Publicado: (2018)

FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c
por: Lam, Andy K. Y., et al.
Publicado: (2013)

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells
por: Chesnokov, Mikhail S., et al.
Publicado: (2021)

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
por: Liu, Cassie, et al.
Publicado: (2021)

Overview of Subcutaneous Metastatic Melanoma
por: Mozzillo, Nicola
Publicado: (2021)

Metastatic Progression of Human Melanoma
por: Tímár, József, et al.
Publicado: (2023)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

PIN1 is a new therapeutic target of craniosynostosis
por: Shin, H R, et al.
Publicado: (2018)

Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC
por: Tan, Jian, et al.
Publicado: (2023)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma
por: Ito, Takamichi, et al.
Publicado: (2016)

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3
por: Zhang, Zhenwang, et al.
Publicado: (2019)

Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting
por: Yu, Chaosheng, et al.
Publicado: (2020)

From Melanocyte to Malignant Metastatic Melanoma
por: Manga, Prashiela, et al.
Publicado: (2010)

p53: Pro-aging or pro-longevity?
por: de Keizer*, Peter L.J., et al.
Publicado: (2010)

Separase Inhibitor Sepin-1 Inhibits Foxm1 Expression and Breast Cancer Cell Growth
por: Zhang, Nenggang, et al.
Publicado: (2018)

Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma
por: Cheng, Chi-Wai, et al.
Publicado: (2020)

Identification of a potent and selective covalent Pin1 inhibitor
por: Pinch, Benika J., et al.
Publicado: (2020)

FoxM1 Induces CCl2 Secretion From Hepatocytes Triggering Hepatic Inflammation, Injury, Fibrosis, and Liver Cancer
por: Filliol, Aveline, et al.
Publicado: (2020)

Maintenance and repair of an aging life cycle
por: Baar, Marjolein P., et al.
Publicado: (2017)

FoxM1 is Upregulated in Osteosarcoma and Inhibition of FoxM1 Decreases Osteosarcoma Cell Proliferation, Migration, and Invasion
por: Zhu, Xia, et al.
Publicado: (2020)

Wiring the oncogenic circuitry: Pin1 unleashes mutant p53
por: Napoli, Marco, et al.
Publicado: (2011)

The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model
por: Reese, Shannon, et al.
Publicado: (2010)

Pin1At regulates PIN1 polar localization and root gravitropism
por: Xi, Wanyan, et al.
Publicado: (2016)

Novel treatment paradigms for metastatic uveal melanoma
por: Patel, Sapna P., et al.
Publicado: (2022)

FOXM1D potentiates PKM2‐mediated tumor glycolysis and angiogenesis
por: Zhang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ehn07givhkm6498t9cbld1bepg